Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities

Overview of attention for article published in OncoTargets and therapy, July 2013

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

googleplus: 1 Google+ user

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 28 Mendeley

Summary Google+ Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma

Article in Cancer Letters (April 2024)

Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma

Article in Frontiers in Oncology (August 2020)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Article in Frontiers in Oncology (May 2020)